Clinical Trials
20 trialsNCT06090669 2026-05-22
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT03816319 2026-05-18
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
National Cancer Institute (NCI)
Phase 1 Suspended
NCT02101944 2024-05-17
Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Completed
NCT02231853 2019-12-17
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT00735930 2015-04-02
Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00104962 2014-06-11
Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 1 Completed
NCT00005845 2013-12-16
Tipifarnib in Treating Patients With Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 1 Completed
NCT00049686 2013-07-18
VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 1 Completed
NCT00064090 2013-07-18
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00070538 2013-07-18
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies
National Cancer Institute (NCI)
Phase 1 Completed
NCT00278330 2013-04-02
Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00005967 2013-02-11
Tipifarnib in Treating Patients With Advanced Hematologic Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00095797 2013-02-08
XK469R in Treating Patients With Refractory Hematologic Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00005064 2013-01-23
PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 1 Completed
NCT00006213 2013-01-23
BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00087204 2013-01-23
Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00098826 2013-01-11
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 1 Completed
NCT00012376 2013-01-09
Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00080925 2012-03-08
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00001533 2006-07-17
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine
National Institutes of Health Clinical Center (CC)
Phase 1 Completed